Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Procter & Gamble Enters Into Agreement With Warner Chilcott
Procter & Gamble and Warner Chilcott have sealed an agreement for the sale of P&G’s global pharmaceuticals business to Warner Chilcott for a cash payment of $3.1 billion.
Procter & Gamble and Warner Chilcott have sealed an agreement for the sale of P&G’s global pharmaceuticals business to Warner Chilcott for a cash payment of $3.1 billion.
PCI Biotech (PCI) has initiated the phase I/II trial with the first patient treatment with its lead candidate, Amphinex. PCI’s proprietary photosensitiser Amphinex is in the study combined
NovaDel has received a milestone payment of approximately $150,000 from Velcera relating to its License and Development Agreement with the latter. The agreement provides Velcera with a license
CSL Biotherapies (CSL) has initiated the US clinical trials of its candidate Influenza A/H1N1 2009 vaccine. Reportedly, studies will determine the safety of CSL’s candidate vaccine and its
Seattle Genetics has completed enrollment in its pivotal clinical trial of brentuximab vedotin (SGN-35), for relapsed and refractory Hodgkin lymphoma. Brentuximab vedotin is an antibody-drug conjugate (ADC) targeted
Tikcro has reported that the US Department of Health and Human Services (HHS) has granted orphan drug status to BioCancell’s BC-819 drug. It is currently in phase I/IIa
Aperio Technologies has received clearance from the FDA to market the IHC HER2 Breast Tissue Tunable Image Analysis application, available through its patented digital pathology platform. The application
Valeant has reported preliminary results from its phase IIa proof-of-concept clinical trial of retigabine, for the treatment of pain associated with postherpetic neuralgia (PHN). Reportedly, retigabine was generally
RegeneRX Biopharmaceuticals has received a Notice of Allowance in Europe for its application – Inhibition or Reversal of Skin Aging by Actin-Sequestering Peptides. Reportedly, the patent covers methods,
NovaDel Pharma has received a payment of approximately $150,000 from Velcera, relating to its License and Development Agreement with Velcera dated June 22, 2004. Reportedly, the agreement provides